AC Immune (NASDAQ:ACIU) Share Price Crosses Below 50-Day Moving Average – Time to Sell?

AC Immune SA (NASDAQ:ACIU)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.71 and traded as low as $2.60. AC Immune shares last traded at $2.64, with a volume of 161,167 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Stock Performance

The firm has a market cap of $261.20 million, a price-to-earnings ratio of -5.74 and a beta of 1.30. The business’s 50 day moving average price is $2.71 and its 200-day moving average price is $3.07.

Institutional Investors Weigh In On AC Immune

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after acquiring an additional 94,191 shares during the period. Northern Trust Corp acquired a new stake in AC Immune during the fourth quarter worth about $1,088,000. Dimensional Fund Advisors LP raised its stake in AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock worth $355,000 after acquiring an additional 74,358 shares during the period. Geode Capital Management LLC raised its stake in AC Immune by 9.9% during the fourth quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock worth $173,000 after acquiring an additional 5,794 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in AC Immune during the fourth quarter worth about $118,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.